Literature DB >> 19667292

Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection.

Michelle M Nerandzic1, Michael J Pultz, Curtis J Donskey.   

Abstract

Proton pump inhibitors (PPIs) have been associated with Clostridium difficile infection (CDI) in several recent studies. However, other studies have not shown this association, and the mechanism by which PPIs might promote CDI has not been elucidated. We hypothesized two possible mechanisms of causation: first, by raising pH, PPIs may prevent gastric contents from killing C. difficile spores; second, gastric contents of PPI-treated patients may promote germination and outgrowth of C. difficile spores. Survival rates of spores from six different strains of C. difficile in acidic gastric contents were assessed using quantitative cultures on selective media. Germination and outgrowth of spores were assessed by heat shock at 80 degrees C, phase-contrast microscopy, and ethanol shock after incubation for 24 h in the gastric contents of patients and in the gastric, small intestinal, and cecal contents of mice. C. difficile spores survived and remained dormant in nonbilious gastric contents with acidic pH. Germination did not occur in unmodified gastric contents of patients but did occur with the addition of taurocholic acid and amino acids. In mice, germination did not occur in gastric contents but did occur in small intestinal and cecal contents. In summary, C. difficile spores survived in acidic gastric contents and did not undergo germination and outgrowth in gastric contents, probably due to lack of essential germinants, such as taurocholic acid. Our results suggest that the effects of PPIs in the stomach do not contribute to the pathogenesis of CDI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667292      PMCID: PMC2764230          DOI: 10.1128/AAC.00252-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole.

Authors:  V G Loo; C A Fallone; E De Souza; J Lavallée; A N Barkun
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

2.  Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster.

Authors:  K H Wilson; J N Sheagren; R Freter
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

3.  Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon.

Authors:  J D Kaunitz; G Sachs
Journal:  J Biol Chem       Date:  1986-10-25       Impact factor: 5.157

4.  Gastric acid suppression does not promote clostridial diarrhoea in the elderly.

Authors:  S Shah; A Lewis; D Leopold; F Dunstan; K Woodhouse
Journal:  QJM       Date:  2000-03

5.  A defined growth medium for Clostridium difficile.

Authors:  T Karasawa; S Ikoma; K Yamakawa; S Nakamura
Journal:  Microbiology       Date:  1995-02       Impact factor: 2.777

6.  Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.

Authors:  B R Dalton; T Lye-Maccannell; E A Henderson; D R Maccannell; T J Louie
Journal:  Aliment Pharmacol Ther       Date:  2008-12-19       Impact factor: 8.171

Review 7.  Clostridium difficile-associated diarrhea in adults.

Authors:  Susan M Poutanen; Andrew E Simor
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

8.  Circadian variations in gastric acid and pepsin secretion and intragastric bile acid in patients with reflux esophagitis and in healthy controls.

Authors:  S Fiorucci; E Distrutti; F Di Matteo; P Brunori; L Santucci; E Mallozzi; U Bigazzi; A Morelli
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

9.  Bile acid concentrations in the gastric juice of patients with erosive oesophagitis.

Authors:  B J Collins; G Crothers; R J McFarland; A H Love
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

10.  Improved medium for sporulation of Clostridium perfringens.

Authors:  C L Duncan; D H Strong
Journal:  Appl Microbiol       Date:  1968-01
View more
  12 in total

1.  Clostridium difficile infection in older adults.

Authors:  Robin Lp Jump
Journal:  Aging health       Date:  2013-08-01

Review 2.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

3.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

4.  Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients.

Authors:  Matt Pappas; Sanjay Jolly; Sandeep Vijan
Journal:  J Gen Intern Med       Date:  2015-11-09       Impact factor: 5.128

5.  Clinical predictors of fulminant colitis in patients with Clostridium difficile infection.

Authors:  Mohit Girotra; Vivek Kumar; Javaid M Khan; Pamela Damisse; Rtika R Abraham; Vikas Aggarwal; Sudhir K Dutta
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485

Review 6.  Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis.

Authors:  Imad M Tleyjeh; Aref A Bin Abdulhak; Muhammad Riaz; Faisal A Alasmari; Musa A Garbati; Mushabab AlGhamdi; Abdur Rahman Khan; Mohamad Al Tannir; Patricia J Erwin; Talal Ibrahim; Abed Allehibi; Larry M Baddour; Alex J Sutton
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

7.  Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.

Authors:  Charlie T Seto; Patricio Jeraldo; Robert Orenstein; Nicholas Chia; John K DiBaise
Journal:  Microbiome       Date:  2014-11-25       Impact factor: 14.650

8.  Metabolism of bile salts in mice influences spore germination in Clostridium difficile.

Authors:  Jennifer L Giel; Joseph A Sorg; Abraham L Sonenshein; Jun Zhu
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

9.  Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection.

Authors:  Malin Inghammar; Henrik Svanström; Marianne Voldstedlund; Mads Melbye; Anders Hviid; Kåre Mølbak; Björn Pasternak
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

Review 10.  Role of microbiota and innate immunity in recurrent Clostridium difficile infection.

Authors:  Stefano Bibbò; Loris Riccardo Lopetuso; Gianluca Ianiro; Teresa Di Rienzo; Antonio Gasbarrini; Giovanni Cammarota
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.